Response Asessment News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Response Asessment. Real-time updates on events, politics, business and more.

Tovorafenib Under Review for Relapsed or Progressive Pediatric Low-Grade Glioma

November 2, 2023

The FDA has accepted for priority review the new drug application for tovorafenib to treat relapsed or progressive pediatric low-grade glioma.

Drug Administration Response Asessment Neuro Oncology High Grade Glioma Prescription Drug User Fee Act Priority Review

Source: cancertherapyadvisor.com

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

October 30, 2023

Priority review granted with PDUFA target action date of April 30, 2024BRISBANE, Calif., Oct. 30, 2023 -- Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to...

United States Jeremy Bender Laura Cooper Oncology Consortium Head Of Communications Exchange Commission

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Response Asessment News Today

Tovorafenib Under Review for Relapsed or Progressive Pediatric Low-Grade Glioma

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Explore More Categories